FOR IMMEDIATE RELEASE Covington, KY, December 10, 2020
Bexion Pharmaceuticals, Inc., a clinical stage biotech company focused on the discovery and development of life-changing treatments by leveraging the lysosome’s roles in solid tumors and cell death with an initial focus on cancer, announced today the database lock for the Phase 1 study of BXQ-350 in adult patients with advanced solid tumors. Bexion presented interim results from this study at the American Society of Clinical Oncology (ASCO) 2020 Virtual Meeting in June.
The phase 1 trial of BXQ-350 was conducted at the Ohio State University Comprehensive Cancer Center, the University of Cincinnati Barrett Center, the University of Kentucky Markey Cancer Center and the University of New Mexico Cancer Center. The study enrolled 86 patients, who had failed prior therapies with over 20 types of advanced solid tumors, including 20 patients with Glioblastoma Multiforme (GBM). BXQ-350 exhibited a very strong safety and tolerability profile with no Dose Limiting Toxicities (DLTs) and only 1 Grade 4 Serious Adverse Event (SAE), which was resolved. Two GBM patients and one Colorectal patient have been moved to a long-term trial, continuing on BXQ-350.
“We are thrilled to reach this milestone and are looking forward to processing and analyzing this trial data” said Dr. Ray Takigiku, PhD, President and CEO at Bexion Pharmaceuticals. “We are further excited to continue to pursue our Phase 2 studies in DIPG/DMG as previously announced, and two others to be announced in 2021”.
About Bexion Pharmaceuticals
Bexion Pharmaceuticals is a clinical-stage biopharmaceutical company developing BXQ-350, a first-in-class agent composed of the multifunctional, lysosomal activator protein, Saposin C and phosphatidylserine. BXQ-350 has demonstrated pre-clinical antitumor effects in vitro and in vivo, particularly in brain and other solid tumors, including those that may lead to brain metastases. Bexion has completed a multi-site first-in-human Phase 1 clinical trial of BXQ-350 for solid tumors and gliomas. Database lock on Bexion’s Phase 1 Pediatric Trial was completed earlier this year.
Media Contact: Margaret van Gilse ●859.757.1652 ● [email protected].
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause Bexion’s actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. Bexion has in some cases identified forward-looking statements by using words such as “anticipates,” “believes,” “hopes,” “estimates,” “looks,” “expects,” “plans,” “intends,” “goal,” “potential,” “may,” “suggest,” and similar expressions. Among other factors that could
cause actual results to differ materially from those expressed in forward-looking statements are Bexion’s need for, and the availability of, substantial capital in the future to fund its operations and research and development; the fact that Bexion’s compounds may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. You should not place undue reliance on any forward-looking statements. Bexion undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.